The Union Health Ministry has proposed amendments to the Medical Devices Rules, 2017 aimed at significantly reducing the time required to grant manufacturing licences for medical devices across all risk categories.
The move is designed to improve ease of doing business, enhance regulatory efficiency, and ensure quicker availability of quality medical devices in India while maintaining safety, performance, and compliance standards. Under the existing framework, medical devices are classified into four risk-based categories—Class A, B, C, and D—with Class D representing the highest-risk devices such as cardiac stents and implants. The proposed changes introduce shorter statutory timelines for approval processes. For Class B devices, which include low to moderate risk products like blood pressure monitors and pulse oximeters, the approval timeline is proposed to be reduced from 140 days to 115 days. For higher-risk Class C and Class D devices, which includes cardiac stents, hip and knee implants, and other orthopaedic implants, the timeline is proposed to be cut from 105 days to 90 days.
The draft amendments also define clearer timelines for each stage of the approval process, including application scrutiny, audits by notified bodies, compliance verification, and licence issuance. The reform is expected to streamline regulatory procedures, support domestic manufacturing, and strengthen India’s medical device ecosystem by enabling faster market entry for manufacturers.
